Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany

Deb, Arijita; Podmore, Bélène; Barnett, Rosemarie; Beier, Dominik; Galetzka, Wolfgang; Qizilbash, Nawab; Haeckl, Dennis; Mihm, Sarah; Johnson, Kelly; Weiß, Thomas

doi:10.1017/s0950268822001182

Cited by 5 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21] Age- and risk-specific annual incidence of inpatient and outpatient all-cause CAP, respectively, were based on a recent study that employed 2016-2019 data and age-specific population distributions. [3,16,18]…”

Section: Methodsmentioning

confidence: 99%

“…Annual IPD case-fatality risks (CFRs) were estimated by age and risk profile using age-specific disease rates, age-specific population distributions by risk profile, and risk-specific disease rates (Supplementary Material Table 6). [17,18,20] Age- and risk-specific CFRs due to all-cause CAP in the inpatient settings, were based on published estimates by Deb et al and adjusted using age-specific population distributions by risk profile (Supplementary Material Table 7). [17,18] In the outpatient setting, CFRs were extracted from a published Robert-Koch-Institute analysis.…”

Section: Methodsmentioning

confidence: 99%

“…[17,18,20] Age- and risk-specific CFRs due to all-cause CAP in the inpatient settings, were based on published estimates by Deb et al and adjusted using age-specific population distributions by risk profile (Supplementary Material Table 7). [17,18] In the outpatient setting, CFRs were extracted from a published Robert-Koch-Institute analysis. [23] Age-specific all-cause German mortality was apportioned across risk groups based on assumed relative risk for mortality and age-specific risk distributions Supplementary Material Table 8).…”

Section: Methodsmentioning

confidence: 99%

“…Annual incidence of IPD was estimated by age and risk profile using age-specific disease rates, age-specific population distributions by risk profile, and risk-specific disease rates. [17][18][19][20] IPD rates were apportioned between bacteremia and meningitis based on hospitalization data published by the Federal Statistical Office. [21] Ageand risk-specific annual incidence of inpatient and outpatient all-cause CAP, respectively, were based on a recent study that employed 2016-2019 data and age-specific population distributions.…”

Section: Model Estimationmentioning

confidence: 99%

“…[21] Ageand risk-specific annual incidence of inpatient and outpatient all-cause CAP, respectively, were based on a recent study that employed 2016-2019 data and age-specific population distributions. [3,16,18] Serotype Coverage. Values employed for serotype coverage are summarized in Supplementary Material (Tables 9-10).…”

Section: Model Estimationmentioning

confidence: 99%

See 4 more Smart Citations

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Kuehne

Achtert²,

Pueschner³

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives. Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugate vaccines (PCVs) with expanded coverage have the potential to reduce the pneumococcal disease burden among adults. Methods. Using a Markov model, we evaluated the lifetime outcomes/costs comparing 20-valent PCV (PCV20) with standard of care (SC) vaccination for prevention of CAP and IPD among adults aged 60 years and at-risk adults aged 18-59 years in Germany. PCV20 also was compared with sequential vaccination with 15-valent PCV (PCV15) followed by PPV23 in a scenario analysis. Results. Use of PCV20 vs. SC would prevent 54,333 hospitalizations, 26,368 outpatient CAP cases, 10,946 disease-related deaths yield 74,694 additional life-years (LYs), while lowering total medical costs by 363.2M Euro. PCV20 was cost saving (i.e., dominant) versus SC. Scenario analysis results suggest that the use of PCV20 would also prevent more cases and deaths, yield more LYs, and result in lower costs than using PCV15→PPV23. Conclusions. One dose of PCV20 among adults aged 60 years and adults aged 18-59 years with moderate- and high-risk conditions would substantially reduce pneumococcal disease, save lives, and be cost saving compared with SC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Model Estimationmentioning

confidence: 99%

Section: Model Estimationmentioning

confidence: 99%

See 3 more Smart Citations

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Kuehne

Achtert²,

Pueschner³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis

Ta,

Kühne,

Laurenz

et al. 2024

Infect Dis Ther

View full text Add to dashboard Cite

Introduction Since 2009, a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) has been included by Germany’s Standing Committee on Vaccinations for infants, resulting in major reductions in pneumococcal disease (PD). Higher-valent vaccines may further reduce PD burden. This cost-effectiveness analysis compared 20-valent PCV (PCV20) under a 3+1 schedule with 15-valent PCV (PCV15) and PCV13, both under 2+1 schedule, in Germany’s pediatric population. Methods A Markov model with annual cycles over a 10-year time horizon was adapted to simulate the clinical and economic impact of pediatric vaccination with PCV20 versus lower-valent PCVs in Germany. The model used PCV13 clinical effectiveness and impact studies as well as PCV7 efficacy studies for vaccine direct and indirect effect estimates. Epidemiologic, utility, and medical cost inputs were obtained from published sources. Benefits and costs were discounted at 3% from a German societal perspective. Outcomes included PD cases, deaths, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Results In the base case, PCV20 provided greater health benefits than PCV13, averting more cases of invasive pneumococcal disease (IPD; 15,301), hospitalized and non-hospitalized pneumonia (460,197 and 472,365, respectively), otitis media (531,634), and 59,265 deaths over 10 years. This resulted in 904,854 additional QALYs and a total cost saving of €2,393,263,611, making PCV20 a dominant strategy compared with PCV13. Compared to PCV15, PCV20 was estimated to avert an additional 11,334 IPD, 704,948 pneumonia, and 441,643 otitis media cases, as well as 41,596 deaths. PCV20 was associated with a higher QALY gain and lower cost (i.e., dominance) compared with PCV15. The robustness of the results was confirmed through scenario analyses as well as deterministic and probabilistic sensitivity analyses. Conclusion PCV20 3+1 dominated both PCV13 2+1 and PCV15 2+1 over 10 years. Replacing lower-valent PCVs with PCV20 would result in greater clinical and economic benefits, given PCV20’s broader serotype coverage. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-024-00977-4.

show abstract

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Kühne,

Achtert,

Püschner

et al. 2023

Expert Review of Vaccines

View full text Add to dashboard Cite

Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany

Cited by 5 publications

References 47 publications

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Contact Info

Product

Resources

About